GlassScriptPhysician profile
Jane B Ayala
NPI 1093914681
$66,542.48
in general payments reported to CMS, 2019-2025
38 companies · $3,032 in 2025
The $3,032 reported for 2025 was more than what 77% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $15K · 2021: $21K · 2022: $7,146 · 2023: $2,728 · 2024: $2,647 · 2025: $3,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,306 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,306.11 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $44,135.89 | 2019-2025 | Benlysta, Nucala |
| Horizon Therapeutics Plc | $3,955.21 | 2019-2023 | Krystexxa |
| Amgen INC. | $3,066.23 | 2019-2025 | Krystexxa, Enbrel, Otezla |
| Janssen Biotech, INC. | $1,716.67 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,533.88 | 2019-2025 | |
| Ucb, INC. | $1,310.99 | 2019-2025 | Cimzia, Bimzelx, Briviact |
| Pfizer INC. | $1,238.34 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,225.87 | 2020-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $1,224.92 | 2019-2025 | Orencia |
| Lilly USA, LLC | $962.60 | 2019-2024 | Taltz |
| Genentech USA, INC. | $809.24 | 2019-2025 | Actemra, Rituxan, Gazyva |
| Astrazeneca Pharmaceuticals LP | $789.08 | 2021-2025 | Saphnelo |
| Genzyme Corporation | $756.51 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $665.01 | 2022-2024 | Purified Cortrophin Gel |
| Pacira Therapeutics, INC. | $635.35 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $353.49 | 2019-2025 | Euflexxa |
| Abbvie INC. | $322.84 | 2020-2025 | Skyrizi |
| Mallinckrodt Enterprises LLC | $294.87 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $165.51 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $159.64 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $153.82 | 2023-2025 | Tyenne, Idacio |
| Organon LLC | $151.00 | 2024-2025 | Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.48 | 2020-2023 | Cyltezo |
| Hikma Pharmaceuticals USA | $140.60 | 2019-2023 | Mitigare |
| Radius Health, INC. | $108.41 | 2020-2025 | Tymlos |
| Medexus Pharma, INC. | $87.84 | 2019 | |
| Aurinia Pharma U.S., INC. | $75.46 | 2024-2025 | Lupkynis |
| Celltrion USA INC. | $59.86 | 2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $49.36 | 2019-2020 | |
| Abbott Laboratories | $45.20 | 2019-2024 | Proclaim |
| Octapharma USA, INC. | $40.00 | 2024-2025 | Octagam Immune Globulin (Human) |
| Invivyd INC | $39.74 | 2025 | Pemgarda |
| Bayer Healthcare Pharmaceuticals INC. | $30.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $29.85 | 2019-2023 | |
| Sandoz INC. | $17.02 | 2023 | Hyrimoz |
| Kiniksa Pharmaceuticals International, Plc | $16.53 | 2024 | Arcalyst |
| Antares Pharma, INC. | $15.19 | 2019 | |
| Avion Pharmaceuticals | $13.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Ayala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.